Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease

Cytokine

Volumn 60, Issue 3, 2012, Pages 681-685

  Hamada, Hiromichi ^a   Suzuki, Hiroyuki ^b   Abe, Jun ^c   Suzuki, Yoichi ^d   Suenaga, Tomohiro ^b   Takeuchi, Takashi ^b   Yoshikawa, Norishige ^b   Shibuta, Shoichi ^e   Miyawaki, Masakazu ^e   Oishi, Ko ^f   Yamaga, Hironobu ^g   Aoyagi, Noriyuki ^h   Iwahashi, Seiji ⁱ   Miyashita, Ritsuko ^j   Honda, Takafumi ^a   Onouchi, Yoshihiro ^d   Terai, Masaru ^a   Hata, Akira ^d  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Social Insurance Kinan Hospital   (Japan)

^f Hashimoto Municipal Hospital   (Japan)

^g Naga Municipal Hospital   (Japan)

^h WAKAYAMA ROSAI HOSPITAL   (Japan)

ⁱ Hidaka General Hospital   (Japan)

^j Izumiotsu Municipal Hospital   (Japan)

more..

Author keywords

Cyclosporine; IL 6; Immunoglobulin; Kawasaki disease; Soluble IL 2 receptor

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; THERAPY RESISTANCE;

CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84867997010     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.006     Document Type: Article

References (24)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of fingers and toes in children: clinical observation of 50 cases. Jpn J Allergol 1967, 16:178-222.
2. Nakamura Y., Yashiro M., Uehara R., Oki I., Kayaba K., Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol 2008, 18:167-172.
3. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New Engl J Med 1991, 324:1633-1639.
4. Takeshita S., Kawamura Y., Nakatani K., Tujimoto H., Tokutomi T. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. Clin Pediatr (Phila) 2005, 44:423-426.
5. Lang B.A., Yeung E.S., Oen K.G., Malleson P.N., Huber A.M., Riley M., et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006, 33:803-809.
6. Hashino K., Ishii M., Iemura M., Akagi T., Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211-217.
7. Furukawa T., Kishiro M., Akimoto K., Nagata S., Shimizu T., Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008, 93:142-146.
8. Burns J.C., Mason W.H., Hauger S.B., Janai H., Bastian J.F., Wohrley J.D., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146:662-667.
9. Burns J.C., Best B.M., Mejias A., Mahony L., Fixler D.E., Jafri H.S., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833-836.
10. Mori M., Imagawa T., Katakura S., Miyamae T., Okuyama K., Ito S., et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004, 14:43-47.
11. Raman V., Kim J., Sharkey A., Chatila T. Response of refractory Kawasaki disease to pulse steroid and Cyclosporine A therapy. Pediatr Infect Dis J 2001, 20:635-637.
12. Lee T.J., Kim K.H., Chun J.K., Kim D.S. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008, 49:714-718.
13. Onouchi Y., Gunji T., Burns J.C., Shimizu C., Newburger J.W., Yashiro M., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008, 40:35-42.
14. Suzuki H., Terai M., Hamada H., Honda T., Suenaga T., Takeuchi T., et al. Cyclosporin A treatment for refractory Kawasaki disease - a pilot study of 28 patients with Kawasaki disease resistant to both initial and additional IVIG. Ped Infect Dis J 2011, 30:871-876.
15. Ueno Y., Takano N., Kanegane H., Yokoi T., Yachie A., Miyawaki T., et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illness. Clin Exp Immunol 1989, 76:337-342.
16. Matsubara T., Furukawa S., Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 116:592-596.
17. Lang B.A., Silverman E.D., Laxer R.M., Rose V., Nelson D.L., Rubin L.A. Serum-soluble interleukin-2 receptor levels in Kawasaki disease. J Pediatr 1990, 116:592-596.
18. Furukawa S., Matsubara T., Yone K., Hirono Y., Okumura K., Yabuta K. Kawasaki disease differs from analyractoid purpura and measles with regard to tumor necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 1992, 151:44-47.
19. Terai M., Jibiki T., Harada A., Terashima Y., Yasukawa K., Tateno S., et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment. J Leukoc Biol 1999, 65:566-572.
20. Suzuki H., Suenaga T., Takeuchi T., Shibuta S., Yoshikawa N. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatl Int 2010, 52:785-789.
21. Japanese Kawasaki disease Research Committee Diagnostic guidelines of Kawasaki disease 2002, Japanese Kawasaki disease Research Committee, Tokyo. 5th ed.
22. Tremoulet A.H., Pancoast P., Franco A., Bujold M., Shimizu C., Onouchi Y., et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012, (Apr 6). [Epub ahead of print].
23. Lin C.Y., Lin C.C., Hwang B., Vhiang B.N. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr 1993, 152:309-312.
24. Ichiyama T., Yoshitomi T., Nishikawa M., Fujiwara M., Matsubara T., Hayashi T., et al. NF-kB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001, 99:373-377.